Genelux (GNLX) Gains from Investment Securities (2022 - 2026)
Genelux (GNLX) recorded quarterly Gains from Investment Securities of $18492.0 in Q1 2026, down 99.72% quarter-over-quarter from $6.7 million in Q4 2025.
Genelux (GNLX) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Genelux's Gains from Investment Securities history runs 5 years deep, the most recent figure standing at $18492.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities changed N/A year-over-year to $18492.0; the TTM figure through Mar 2026 stood at $18492.0 (changed N/A YoY), while the FY2025 annual figure was $6.7 million, up 24.87% from the prior year.
- Gains from Investment Securities was $18492.0 for Q1 2026 at Genelux, down from $6.7 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $6.7 million in Q4 2025 to a low of $1500.0 in Q2 2025.
- Historically, Gains from Investment Securities has averaged $2.3 million across 5 years, with a median of $604128.5 in 2022.
- The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities surged 1965.87% in 2023, then sank 95.24% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $247785.0 in 2022, then soared by 1965.87% to $5.1 million in 2023, then climbed by 5.01% to $5.4 million in 2024, then grew by 24.87% to $6.7 million in 2025, then tumbled by 99.72% to $18492.0 in 2026.
- The last three Gains from Investment Securities figures came in at $18492.0 (Q1 2026), $6.7 million (Q4 2025), and $960472.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,492.00 |
| Mar 31, 2026 | 18,492.00 |
| Dec 31, 2025 | 6.71 Mn |
| Dec 31, 2025 | 6.71 Mn |
| Sep 30, 2025 | 960,472.00 |
| Sep 30, 2025 | 960,472.00 |
| Jun 30, 2025 | 1,500.00 |
| Jun 30, 2025 | 1,500.00 |
| Dec 31, 2024 | 5.38 Mn |
| Dec 31, 2024 | 5.38 Mn |
| Sep 30, 2024 | 233,376.00 |
| Sep 30, 2024 | 233,376.00 |
| Jun 30, 2024 | 31,500.00 |
| Jun 30, 2024 | 31,500.00 |
| Mar 31, 2024 | 5.12 Mn |
| Mar 31, 2024 | 5.12 Mn |
| Dec 31, 2023 | 5.12 Mn |
| Dec 31, 2023 | 5.12 Mn |
| Sep 30, 2023 | 57,900.00 |
| Sep 30, 2023 | 57,900.00 |